7.3 – Conditional Probability and Evidence Based Medicine

Conditional probability and risk communication.

Conditional probabilities can be used to accurately and effectively convey the risk of specific health outcomes to patients and the public. Tools introduced in this chapter help move from an initial assessment of disease risk to a revised probability after a test result is returned. Although there are other interpretations, here we frame EBM — evidence-based-medicine — as a form of Bayesian decision-making.

This sub-chapter covers a lot of ground. We begin by addressing how probability of multiple events are calculated assuming each event is independent. The assumption of independence is then relaxed, and how to determine probability of an event happening given another event has already occurred, conditional probability, is introduced. Use of conditional probability to interpret results of a clinical test are also introduced, along with the concept of EBM. We also introduce Bayes’ rule and Bayesian probability.

Probability and independent events.

Probability distributions are mathematical descriptions of the probabilities of how often different possible outcomes occur. We also introduced basic concepts related to working with the probabilities involving more than one event.

For review, for independent events, you multiply the individual chance that each event occurs to get the overall probability.

Example of multiple, independent events.

Figure 1. Now that is a box full of kittens. Creative Commons License, source: https://www.flickr.com/photos/83014408@N00/160490011

Figure 1. Now that’s a box full of kittens. Creative Commons License, source: https://www.flickr.com/photos/83014408@N00/160490011.

What is the chance of five kittens in a litter of five to be of the same sex? In feral cat colonies, siblings in a litter share the same mother, but not necessarily the same father, superfecundation. Singleton births are independent events, thus the probability of the first kitten is female is 50%; the second kitten is female, also 50%; and so on. We can multiply the independent probabilities (hence, the multiplicative rule), to get our answer:

kittens <- c(0.5, 0.5, 0.5, 0.5, 0.5)
prod(kittens)
[1] 0.03125

Probabilistic risk analysis.

Risk analysis is the use of information to identify hazards and to estimate the risk. A more serious example. Consider the 1986 Space Shuttle Challenger Disaster (Hastings 2003). Among the crew killed was Ellison Onizuka, the first Asian American to fly in space (Fig 2, first on left back row). Onizuka was born and raised on Hawai`i and graduated from Konawaena High School in 1964.

Figure 2. STS-51-L crew: (front row) Michael J. Smith, Dick Scobee, Ronald McNair; (back row) Ellison Onizuka, Christa McAuliffe, Gregory Jarvis, Judith Resnik. Image by NASA - NASA Human Space Flight Gallery, Public Domain.

Figure 2. STS-51-L crew: (front row) Michael J. Smith, Dick Scobee, Ronald McNair; (back row) Ellison Onizuka, Christa McAuliffe, Gregory Jarvis, Judith Resnik. Image by NASA – NASA Human Space Flight Gallery, Public Domain.

The shuttle was destroyed just 73 seconds after lift off (Fig 3).

Figure 3. Space Shuttle Challenger launches from launchpad 39B Kennedy Space Center, FL, at the start of STS-51-L. Hundreds of shorebirds in flight. Image by NASA - NASA Human Space Flight Gallery, Public Domain.

Figure 3. Space Shuttle Challenger launches from launchpad 39B Kennedy Space Center, FL, at the start of STS-51-L. Hundreds of shorebirds in flight. Image by NASA – NASA Human Space Flight Gallery, Public Domain.

This next section relies on material and analysis presented in the Rogers Commission Report June 1986. NASA had estimated that the probability of one engine failure would be 1 in 100 or 0.01; two engine failures would mean the shuttle would be lost. Thus, the probability of two rockets failing at the same time was calculated as 0.01 X 0.01, which is 0.0001 or 0.01%.

NASA had planned to fly the fleet of shuttles 100 times per year, which would translate to a shuttle failure once in 100 years. The Challenger launch on January 28, 1986, represented only the 25th flight of the shuttle fleet.

One difference on launch day was that  the air temperature at Cape Canaveral was quite low for that time of year, as low as 22 °F overnight.

Attention was pointed at the large O-rings in the boosters (engines). In all, there were six of these O-rings. Testing suggested that, at the colder air temperatures, the chance that one of the rings would fail was 0.023. Thus, the chance of success was only 0.977. Assuming independence, what is the chance that the shuttle would experience O-ring failure?

shuttle <- c(0.977, 0.977, 0.977, 0.977, 0.977, 0.977)
#probability of success then was
prod(shuttle)
[1] 0.869

#and therefore probability of failure was
1 - prod(shuttle)
[1] 0.1303042

Conditional probability of non-independent events.

But in many other cases, independence of events cannot be assumed. The probability of an event given that another event has occurred is referred to as conditional probability. Conditional probability is used extensively to convey risk. We’ve touched on some of these examples already:

  • the risk of subsequent coronary events given high cholesterol;
  • the risk of lung cancer given a person smokes tobacco;
  • the risk of mortality from breast cancer given that regular mammography screening was conducted.

There are many, many examples in medicine, insurance, you name it. It is even an important concept that judges and lawyers need to be able to handle (eg, discussion in Berry 2008).

A trigger warning: what follows is emotional, traumatic material, provided to emphasize the importance of these concepts, and the far-reaching implications understanding conditional probability can have for us.

A now famous example of conditional probability in the legal arena came from arguments over the chance that a husband or partner who beats his wife will subsequently murder her — this was an argument raised by the prosecution during pre-trial in the 1995 O.J. Simpson trial (The People of the State of California v. Orenthal James Simpson), and successfully argued by O.J. Simpson’s attorneys… judge ruled in favor of the defense and evidence of O.J. Simpson’s prior abuse were not included in trial. Gigerenzer (2002, following discussions by others, eg, Good 1995) and others (eg, Skorupski and Wainer 2015), have called this the Defendent’s Fallacy, the reverse of the Prosecutor’s Fallacy, where the more typical scenario is that the prosecution provides a list of probabilities about characteristics of the defendant, leaving the jury to conclude that no one else could have possibly fit the description (Thompson and Shumann 1987).

In the O.J. Simpson case, the argument went something like this. From the CDC we find that the chance of an average woman being murdered by a stranger or an unrelated party was about 1 in 20,000. CDC statistics indicate 1.3 million women are abused each year by their partner or former partner; each year about 1000 women are murdered. One thousand divided by 1.3 million is a small number, so even when there is abuse the argument goes, 99% of the time there is not murder. The Simpson judge ruled in favor of the defense and much of the evidence of prior abuse was excluded.

Something is missing from the defense’s argument. Nicole Brown Simpson did not belong to a population of battered women — she belonged to the population of murdered women. When we ask, if a woman is murdered, what is the chance that she knew her murderer, we find that more than 55% knew their murderer — and of that 55%, 93% were killed by a partner who had a history of prior abuse against the victim.

Instead of looking at all 1.3 million abused women, we isolate a representative cohort of 100,000 abused women to see what mathematically happens to them in a given year:

Group 1: Murdered by their abuser. According to the defense’s rate of 1 in 2,500:

    \begin{align*} \frac{100K}{2.5K} = 40 / women \end{align*}

Group 2: Murdered by someone else:

    \begin{align*} \frac{100K}{20K} = 5 / women \end{align*}

Given that an abused woman was murdered, what is the probability it was done by her abuser?

    \begin{align*} p(\text{abuser is killer} \mid \text{abused \& killed}) = \frac{40}{40+5} \end{align*}

or 89%.

This is a huge difference from how the Defense portrayed the chance, where they wanted the judge to assume every single one of those 2500 abusers is equally likely to have committed the crime. In reality, we must condition the match on all other available evidence.

The key —  Nicole Simpson (and Ron Goldman) were murdered; O.J. Simpson was an ex-partner who had been guilty of assault against Nicole Simpson. Now, it goes from an impossibly small chance, to a much greater chance.  Conditional probability, and specifically Bayes’ rule, is used for these kinds of problems. The defense successfully masked a probability that was heavily stacked against their client.

Bayes’ rule provides guidance for how to update the probability of an event based on new evidence. Named after Thomas Bayes (1701- 1761), more generally, Bayes’ rule, described below, is used to quantify conditional probability. Bayesian probability, where probability is interpreted as reasonably expectation instead of frequency of some event. We discuss Bayesian and Frequentist approaches to hypothesis testing in Chapter 8.2.

Note 1: Following our epidemilogy definitions, women murdered by their abuser (Group 2), epidemiology terms, that would be CER, the exposure rate in controls, whereas abused woman murdered by her abuser (Group 1), that would be EER, the exposure rate in cases.

Diagnosis from testing.

Let’s turn our attention to medicine. A growing practice in medicine is to claim that decision making in medicine should be based on approaches that give us the best decisions.  A search of PubMed texts for “evidence based medicine” found more than 91,944 (13 October 2021, and increase of thirteen thousand since last I looked (10 October, 2019). Evidence based medicine (EBM) is the  “conscientious, explicit, judicious and reasonable use of modern, best evidence in making decisions about the care of individual patients” (Masic et al 2008). By evidence, we may mean results from quantitative, systematic reviews, meta-analysis, of research on a topic of medical interest, eg, Cochrane Reviews.

Note 2: Primary research refers to generating or collecting original data in pursuit of tests of hypotheses. Both systematic reviews and meta-analysis are secondary research or “research on research.” As opposed to a literature review, systematic review make explicit how studies were searched for and included; if enough reasonably similar quantitative data are obtained through this process, the reviewer can combine the data and conduct an analysis to assess whether a treatment is effective (De Vries 2018).

As you know, no diagnostic test is 100% fool-proof. For many reasons, test results come back positive when the person truly does not have the condition — this is a false positive result. Correctly identifying individuals who do not have the condition, 100% – false positive rate, is called the specificity of a test.

Think of specificity in this way — provide the test 100 true negative samples (eg, 100 samples from people who do not have cancer) — how many times out of 100 does the test correctly return a “negative”? If 99 times out of 100, then the specificity rate for this test is 99%. Which is pretty good. But the test results mean more if the condition/disease is common; for rare conditions, even 99% is not good enough. Incorrect assignments are rare, we believe, in part because the tests are generally quite accurate. However, what we don’t consider is that detection and diagnosis from tests also depend on the base rate — how frequent the incidence of the condition is in the population. Paradoxically, the lower the base rate, the poorer diagnostic value even a sensitive test may have.

Note 3: This concept, that the base rate effects clinical relevance of interpreting testing — has really important, real-world consequences. It directly bears on clinical testing of cancer and other relatively rare diseases; it also dramatically influences applicability of highly sensitive tests for drug use in clinical samples.

To summarize our jargon for interpreting a test or assay, so far we have

  • True positive (a), the person has a disease and the test correctly identifies the person as having the disease.
  • False positive (b), test result incorrectly identifies disease; the person does not have the disease, but the test classifies the person as having the disease.
  • False negative (c), test result incorrectly classifies person does not have disease, but the person actually has the disease.
  • True negative (d), the person does not have the disease and the test correctly categorizes the person as not having the disease.
  • Positive predictive value (PPV), the proportion of patients with a positive test result who actually have the disease, PPV = \frac{TP}{TP+FP}.
    • Negative Predictive Value (NPV), the probability that a person who receives a negative test result really does not have the disease, NPV = \frac{TN}{TN+FN}.
  • Sensitivity of test (Se), the proportion of persons who test positive and do have the disease (true positives): Se = \frac{TP}{TP+FN}
    If a test has 75% sensitivity, then out of 100 individuals who do have the disease, then 75 will test positive (TP = true positive).
  • Specificity of a test (Sp), refers to the rate that a test correctly classifies a person that does not have the disease (TN = true negatives): Sp = \frac{TN}{TN+FP}
    If a test has 90% specificity, then out of 100 individuals who truly do not have the disease, then 90 will test negative (= true negatives).

A worked example. A 50 year old male patient is in the doctor’s office. The doctor is reviewing results from a diagnostic test, eg, a FOBT — fecal occult blood test — a test used as a screening tool for colorectal cancer (CRC). The doctor knows that the test has a sensitivity of about 75% and specificity of about 90%. Prevalence of CRC in this age group is about 0.2% (cf NCI SEER). The prevalence is also the prior probability — the baseline rate of the condition in the population before a test is taken. Figure 4 shows our probability tree using our natural numbers approach (Fig 4).

Probability tree for FOBT test; Good test outcomes shown in green: TP stands for true positive and TN stands for true negative. Poor outcomes of a test shown in red: FN stands for false negative and FP stands for false positive.

Figure 4. Probability tree for FOBT test; Good test outcomes shown in green: TP stands for true positive and TN stands for true negative. Poor outcomes of a test shown in red: FN stands for false negative and FP stands for false positive.

Note 4: Since U.S. Preventative Task Force (2021), FOBT has largely been replaced by Fecal Immunochemical Test (FIT): sensitivity 74%, specificity 95%, and Multitarget Stool DNA Test: sensitivity 76%, specificity 90%. Cologuard combines both: sensitivity 92%, specificity 97% (cf discussion in Imperiale et al 2014).

  • The U.S. Supreme Court (Kennedy v. Braidwood Management, Inc) supported USPSTF’s authority to recommend preventive services covered by insurers (see 2025 article by R. Payerchin in Medical Economics).

The associated probabilities for the four possible outcomes of these kinds of tests (eg, what’s the probability of a person who has tested positive in screening tests actually has the disease?) are shown in Table 1.

Table 1. A 2 X 2 table of possible outcomes of a diagnostic test.

Person really has the disease
Test Result Yes No
Positive a
TP
b
FP
Negative c
FN
d
TN

We want the posterior probability — the chance that a positive test result is a true positive. Bayes’ rule is often given in probabilities,

    \begin{align*} p\left ( D\mid \oplus \right )=\frac{p\left ( D \right )\cdot p\left (\oplus\mid D \right )}{[p\left ( D \right )\cdot p\left (\oplus \right )+p\left ( ND \right )\cdot p\left (\oplus \mid ND \right )]} \end{align*}

Bayes’ rule, where truth is represented by either D (the person really does have the disease”) or ND (the person really does not have the disease”) and ⊕ is symbol for “exclusive or” and reads “not D” in this example.

An easier way to see this is to use frequencies and our table instead (Table 1, numbers in Figure 4).

Now, the formula is

    \begin{align*} p\left ( disease \mid positive \right )=\frac{a}{a+b} \end{align*}

Simplified Bayes’ rule, where a is the number of people who test positive and DO HAVE the disease and b is the number of people who test positive and DO NOT have the disease. Thus, p, the posterior probability was

    \begin{align*} p\left ( disease \mid positive \right )=\frac{15}{15+9998} \end{align*}

or 0.15%. Because the condition is so rare (0.2% prior) and the test generates a very high number of False Positives (9,998), getting a positive result actually lowers oour confidence slightly from the base rate (from 0.2% down to 0.15%). This occurs because the test is highly unreliable in screening this specific population — it’s known as the base rate fallacy. Thus, the chance that a positive FOBT test for our 50 year old male patient is 99.85% likely wrong.

Standardized million.

Where did the 100,000 come from? We discussed this in chapter 2: it’s a simple trick to adjust rates to the same population size. We use this to work with natural numbers instead of percent or frequencies. You choose to correct to a standardized population based on the raw incidence rate. A rough rule of thumb:

Table 2. Relationship between standard population size and incidence rate.

Raw IR rate about IR Standard population
1/10 10% 1000
1/100 1% 10,000
1/1000 0.1% 100,000
1/10,000 0.01% 1,000,000
1/100,000 0.001% 10,000,000
1/1,000,000 0.0001% 100,000,000

The raw incident rate is simply the number of new cases divided by the total population.

Per capita rate.

Yet another standard manipulation is to consider the average incidence per person, or per capita rate. The Latin “per capita” translates to “by head” (Google translate), but in economics, epidemiology, and other fields it is used to reflect rates per person. Tuberculosis is a serious infectious disease of primarily the lungs. Incidence rates of tuberculosis in the United States have trended down since the mid 1900s: 52.6 per 100K in 1953 to 2.7 per 100K in 2019 (CDC). Corresponding per capita values are 5.26 x 10-4 and 2.7 x 10-5, respectively. Divide the rate by 100,000 to get per person rate.

Practice and introduce PPV and test decision criteria.

Let’s break these problems down, and in doing so, introduce some terminology common to the field of “risk analysis” as it pertains to evaluating assay and diagnotistc tests in biology and epidemiology. Our first example considers the fecal occult blood test, FOBT, test. Blood in the stool may (or may not) indicate polys or colon cancer (Park et al 2010).

A table like the one shown above (Table 1) will appear again and again throughout this and subsequent chapters, but in different forms. We start with Table 3.

Table 3. A 2 X 2 table of possible outcomes of FOBT test.

Person really has the disease
Yes No
Positive 15 9998 PPV = 15/(15+9998) = 0.15%
Negative 5 89,982 NPV = 89982/(89982+5) = 99.99%

We want to know how good is the test, particularly if the goal is early detection? This is conveyed by the PPV, positive predictive value of the test. Unfortunately, the prevalence of a condition is also at play: the lower the prevalence, the lower the PPV must be, because most positive tests will be false when population prevalence is low.

Youden (1950) proposed a now widely adopted index that summarizes how effective a test is. Youden’s J is the sum of specificity and sensitivity minus one.

    \begin{align*} J = Se+Sp-1 \end{align*}

where Se stands for sensitivity of the test and Sp stands for sensitivity of the test.

Youden’s J takes on values between 0, for a terrible test, and 1, for a perfect test. For our FOBT example, Youden’s J was 0.65. This statistic looks like it’s independent of prevalence, but it’s use as a decision criterion (eg, a cutoff value, above which test is positive, below test is considered negative), assumes that the cost of misclassification (false positives, false negatives) are equal. Prevalence affects number of false positives and false negatives for a given diagnostic test, so any decision criterion based on Youden’s J will also be influenced by prevalence (Smits 2010).

Youden’s J is insensitive to base rates and therefore may be of little practical use in the field. Unsurprisingly, other tools are available, including Matthew’s Correlation Coefficient (MCC),

    \begin{align*} MCC = \frac{(TP X TN) - (FP X FN)}{\sqrt{(TP X FP)(TP + FP)(TN + FP)(TN + FN)}} \end{align*}

and the positive and negtive Clinical Utility Index (CUI+, CUI-),

    \begin{align*} Positive CUI+ = Sensitivity X PPV Negative CUI- = Sensitivity X NPV \end{align*}

or the F1-score,

    \begin{align*} F1-score = 2 X \frac{PPV X Sensitivity}{PPV + Sensitivity} \end{align*}

epiR will calculate Youden’s J, but the others are either calculated by hand or by way of additional packages. So, we’ll provide a function.

R code to calculate testing decision criteria — code genereated with Gemini AI assistance.

run_screening_wizard <- function() {
# 1. Sequential user prompts starting with cell a
cat("--- 2x2 Matrix Entry Wizard ---\n")
a <- as.numeric(readline(prompt = "Enter cell a (True Positives, TP): "))
b <- as.numeric(readline(prompt = "Enter cell b (False Positives, FP): "))
c <- as.numeric(readline(prompt = "Enter cell c (False Negatives, FN): "))
d <- as.numeric(readline(prompt = "Enter cell d (True Negatives, TN): "))

# 2. Map cells to short variables for calculation
tp <- a
fp <- b
fn <- c
tn <- d

# 3. Construct and print the visual 2x2 matrix
user_matrix <- matrix(
c(tp, fp, fn, tn), 
nrow = 2, 
byrow = TRUE,
dimnames = list(Test = c("+", "-"), Disease = c("+", "-"))
)
cat("\n[+] Captured Matrix:\n")
print(user_matrix)

# 4. Run background metrics math
sensitivity <- tp / (tp + fn)
specificity <- tn / (tn + fp)
ppv <- tp / (tp + fp)
if (is.nan(ppv)) ppv <- 0 

youden_j <- sensitivity + specificity - 1
cui_pos <- sensitivity * ppv

f1_score <- 2 * ((ppv * sensitivity) / (ppv + sensitivity))
if (is.nan(f1_score)) f1_score <- 0 

mcc_num <- (tp * tn) - (fp * fn)
mcc_den <- sqrt(as.numeric(tp + fp) * as.numeric(tp + fn) * 
as.numeric(tn + fp) * as.numeric(tn + fn))
mcc <- if (mcc_den == 0) 0 else mcc_num / mcc_den

# 5. Compile into the copy/paste ready console matrix
output_matrix <- matrix(
c(round(youden_j, 4), "No", "Good (Overly optimistic baseline)",
round(mcc, 4), "Yes", "Poor (Correctly captures imbalance)",
round(cui_pos, 4), "Yes", "Unacceptable clinical utility",
round(f1_score, 4), "Yes", "Near-total prediction failure"),
nrow = 4, byrow = TRUE
)

dimnames(output_matrix) <- list(
c("Youden's J Index", "MCC", "CUI+", "F1-Score"),
c("Value", "Base_Rate_Dep", "Console_Interpretation")
)

final_df <- as.data.frame(output_matrix)

# 6. Print and invisibly return the dataframe
cat("\n[+] Resulting Metrics Table (Copy/Paste Ready):\n")
print(final_df)
return(invisible(final_df))
}

# Run the function at the R command prompt.
run_screening_wizard()

End R code.

Thus, using a metric sensitive to low base rate, our FOBT tests are (modified from R output)

Table 4. Decision criteria.

Value Base rate dependent? Interpretation
Youden's \ J 0.65 No Good
MCC 0.0306 Yes Poor
Positive \ Clinical \ Utility \ Index 0.0011 Yes Unacceptable clinical utility
F1-score 0.0030 Yes Near-total prediction failure

Another worked example.  A study on cholesterol-lowering drugs (statins) reported a relative risk reduction of death from cardiac event by 22%. This does not mean that for every 1000 people fitting the population studied, 220 people would be spared from having a heart attack. In the study, the death rate per 1000 people was 32 for the statin versus 41 for the placebo — recall that a placebo is a control treatment offered to overcome potential patient psychological bias (see Chapter 5.4). The absolute risk reduction due to statin is only 41 – 32 or 9 in 1000 or 0.9%. By contrast, relative risk reduction is calculated as the ratio of the absolute risk reduction (9) divided by the proportion of patients who died without treatment (41), which is 22% (LIPID Study Group 1998).

Note that risk reduction is often conveyed as a relative rather than as an absolute number. The distinction is important for understanding arguments based in conditional probability. Thus, the question we want to ask about a test is summarized by absolute risk reduction (ARR) and number needed to treat (NNT), and for problems that include control subjects, relative risk reduction (RRR). We expand on these topics in the next section, 7.4 – Epidemiology: Relative risk and absolute risk, explained.

Evidence Based Medicine.

One culture change in medicine is the explicit intent to make decisions based on evidence (Masic et al 2008). Of course, the joke then is, well, what were doctors doing before, diagnosing without evidence? The comic strip xkcd offers one possible answer (Fig 5).

A summary of "evidence based medical" decisions, perhaps? https://xkcd.com/1619/

Figure 5. A summary of “evidence based medical” decisions, perhaps? “Watson Medical Algorithm,” https://xkcd.com/1619/.

As you can imagine, there’s considerable reflection about the EBM movement (see discussions in response to Accad and Francis 2018, eg, Goh 2018). More practically, our objective is for you to be able to work your way through word problems involving risk analysis. You can expect to be asked to calculate, or at least set up for calculation, any of the statistics listed above (eg, False negative, false positive, etc.). Practice problems are listed at the end of this section, and additional problems are provided to you (Homework 4). You’ll also want to check your work, and in any real analysis, you’d most likely want to use R.

Software.

R has several epidemiology packages, and with some effort, can save you time. Another option is to run your problems in OpenEpi, a browser-based set of tools. OpenEpi is discussed with examples in the next section, 7.4.

Here, we illustrate some capabilities of the epiR package, expanded more also in the next section, 7.4. We’ll use the example from Table 3.

R code

library(epiR) 
Table3 <- matrix(c(15, 5, 9998, 89982), nrow = 2, ncol = 2)
epi.tests(Table3)

R output

         Outcome + Outcome -   Total
Test +          15      9998   10013
Test -           5     89982   89987
Total           20     99980  100000

Point estimates and 95% CIs:
--------------------------------------------------------------
Apparent prevalence *                      0.10 (0.10, 0.10)
True prevalence *                          0.00 (0.00, 0.00)
Sensitivity *                              0.75 (0.51, 0.91)
Specificity *                              0.90 (0.90, 0.90)
Positive predictive value *                0.00 (0.00, 0.00)
Negative predictive value *                1.00 (1.00, 1.00)
Positive likelihood ratio                  7.50 (5.82, 9.67)
Negative likelihood ratio                  0.28 (0.13, 0.59)
False T+ proportion for true D- *          0.10 (0.10, 0.10)
False T- proportion for true D+ *          0.25 (0.09, 0.49)
False T+ proportion for T+ *               1.00 (1.00, 1.00)
False T- proportion for T- *               0.00 (0.00, 0.00)
Correctly classified proportion *          0.90 (0.90, 0.90)
--------------------------------------------------------------
* Exact CIs

Oops! I wanted PPV, which by hand calculation was 0.15%, but R reported “0.00?” This is a significant figure reporting issue. The simplest solution is to submit options(digits=6) before the command, then save the output from epi.tests() to an object and use summary(). For example

options(digits=6)
myEpi <- epi.tests(Table3)
summary(myEpi)

And R returns

     statistic           est        lower        upper
1           ap  0.1001300000 0.0982761568  0.102007072
2           tp  0.0002000000 0.0001221693  0.000308867
3           se  0.7500000000 0.5089541283  0.913428531
4           sp  0.9000000000 0.8981238085  0.901852950
5      diag.ac  0.8999700000 0.8980937508  0.901823014
6      diag.or 27.0000000000 9.8110071871 74.304297826
7         nndx  1.5384615385 1.2265702376  2.456532054
8       youden  0.6500000000 0.4070779368  0.815281481
9       pv.pos  0.0014980525 0.0008386834  0.002469608
10      pv.neg  0.9999444364 0.9998703379  0.999981958
11      lr.pos  7.5000000000 5.8193604069  9.666010707
12      lr.neg  0.2777777778 0.1300251423  0.593427490
13      p.rout  0.8998700000 0.8979929278  0.901723843
14       p.rin  0.1001300000 0.0982761568  0.102007072
15      p.tpdn  0.1000000000 0.0981470498  0.101876192
16      p.tndp  0.2500000000 0.0865714691  0.491045872
17      p.dntp  0.9985019475 0.9975303919  0.999161317
18      p.dptn  0.0000555636 0.0000180416  0.000129662

There we go — pv.pos reported as 0.0014980525, which, after turning to a percent and rounding, we have 0.15%. Note also the additional statistics provided — a good rule of thumb — always try to save the output to an object, then view the object, eg, with summary(). Refer to help pages for additional details of the output (?epi.tests).

What about R Commander menus?

Note 3: Confirmed Fall 2026 — I have not been able to run the EBM plugin successfully! Simply returns an error message — — on data sets which have in the past performed perfectly. Thus, until further notice, do not use the EBM plugin. Instead, use commands in the epiR package. I’m leaving the text here on the chance the error with the plugin is fixed.

Rcmdr has a plugin that will calculate ARR, RRR and NNT. The plugin is called RcmdrPlugin.EBM (Leucuta et al 2014) and it would be downloaded as for any other package via R.

Download the package from your selected R mirror site, then start R Commander.

install.packages("RcmdrPlugin.EBM")

From within R Commander (Fig 6), select

Tools → Load Rcmdr plug-in(s)…

To install an Rcmdr plugin, first go to Rcmdr → Tools → Load Rcmdr plug-in(s)...

Figure 6. To install an Rcmdr plugin, first go to Rcmdr → Tools → Load Rcmdr plug-in(s)…

Next, select from the list the plug-in you want to load into memory, in this case, RcmdrPlugin.EBM (Fig 7).

Select the Rcmdr plugin, then click the "OK" button to proceed.

Figure 7. Select the Rcmdr plugin, then click the “OK” button to proceed.

Restart Rcmdr again (Fig 8),

Select "Yes" to restart R Commander and finish installation of the plug-in.

Figure 8. Select “Yes” to restart R Commander and finish installation of the plug-in.

and the menu “EBM” should be visible in the menu bar (Fig 9).

After restart of R Commander the EBM plug-in is now visible in the menu.

Figure 9. After restart of R Commander the EBM plug-in is now visible in the menu.

Note that you will need to repeat these steps each time you wish to work with a plug-in, unless you modify your .RProfile file. See

Rcmdr → Tools → Save Rcmdr options…

Clicking on the EBM menu item brings up the template for the Evidence Based Medicine module. We’ll mostly work with 2 X 2 tables (eg, see Table 1) , so select the “Enter two-way table…” option to proceed (Fig 10).

Select "Enter two-way table...".

Figure 10. Select “Enter two-way table…”.

And finally, Figure 11 shows the two-way table entry cells along with options. We’ll try a problem by hand then use the EBM plugin to confirm and gain additional insight.

Two-way table Rcmdr EBM plug-in.

Figure 11. Two-way table Rcmdr EBM plug-in.

For assessing how good a test or assay is, use the Diagnosis option in the EBM plugin. For situations with treated and control groups, use Therapy option. For situations in which you are comparing exposure groups (eg, smokers vs non-smokers), use the Prognosis option.

Example.

Here’s a simple one (problem from Gigerenzer 2002).

About 0.01% of men in Germany with no known risk factors are currently infected with HIV. If a man from this population actually has the disease, there is a 99.9% chance the tests will be positive. If a man from this population is not infected, there is a 99.9% chance that the test will be negative. What is the chance that a man who tests positive actually has the disease?

Start with the reference, or base population (Figure 12). It’s easy to determine the rate of HIV infection in the population if you use numbers. For 10,000 men in this group, exactly one man is likely to have HIV (0.0001X10,000), whereas 9,999 would not be infected.

For the man who has the disease it’s virtually certain that his results will be positive for the virus (because the sensitivity rate = 99.9%). For the other 9,999 men, one will test positive (the false positive rate = 1 – specificity rate = 0.01%).

Thus, for this population of men, for every two who test positive, one has the disease and one does not, so the probability even given a positive test is only 100*1/2 = 50%. This would also be the test’s Positive Predictive Value.

Note that if the base rate changes, then the final answer changes! For example, if the base rate was 10%

It also helps to draw a tree to help you determine the numbers (Fig 12)

Draw a probability tree to help with the frequencies.

Figure 12. Draw a probability tree to help with the frequencies.

From our probability tree in Figure 12 it is straight-forward to collect the information we need.

  • Given this population, how many are expected to have HIV? Two.
  • Given the specificity and sensitivity of the assay for HIV, how many persons from this population will test positive? Two.
  • For every positive test result, how many men from this population will actually have HIV? One.

Thus, given this population with the known risk associated, the probability that a man testing positive actually has HIV is 50% (=1/(1+1)).

Use the EBM plugin. Select two-way table, then enter the values as shown in Fig 13.

EBM plugin with data entry

Figure 13. EBM plugin with data entry.

Select the “Diagnosis” option — we are answering the question: How probable is a positive result given information about sensitivity and specificity of a diagnosis test. The results from the EBM functions are given below

Rcmdr> .Table
      Yes No
   +  1    1
   -  0 9998
Rcmdr> fncEBMCrossTab(.table=.Table, .x='', .y='', .ylab='', .xlab='', 
Rcmdr+ .percents='none', .chisq='1', .expected='0', .chisqComp='0', .fisher='0', 
Rcmdr+ .indicators='dg', .decimals=2)
# Notations for calculations
        Disease + Disease -
Test +      "a"         "b" 
Test -      "c"         "d"
# Sensitivity (Se) = 100 (95% CI 2.5 - 100) %. Computed using formula: a / (a + c)
# Specificity (Sp) = 99.99 (95% CI 99.94 - 100) %. Computed using formula: d / (b + d)
# Diagnostic accuracy (% of all correct results) = 99.99 (95% CI 99.94 - 100) %. Computed using formula: (a + d) / (a + b + c + d)
# Youden's index = 1 (95% CI 0.02 - 1). Computed using formula: Se + Sp - 1
# Likelihood ratio of a positive test = 9999 (95% CI 1408.63 - 70976.66). Computed using formula: Se / (Sp - 1)
# Likelihood ratio of a negative test = 0 (95% CI 0 - NaN). Computed using formula: (1 - Se) / Sp
# Positive predictive value = 50 (95% CI 1.26 - 98.74) %. Computed using formula: a / (a + b)
# Negative predictive value = 100 (95% CI 99.96 - 100) %. Computed using formula: d / (c + d)
# Number needed to diagnose = 1 (95% CI 1 - 40.91). Computed using formula: 1 / [Se - (1 - Sp)]

Note that the formulas used to calculate Sensitivity, Specificity, etc., follow our Table 1 (compare to “Notations for calculations”). The use of EBM provides calculations of our confidence intervals.

Questions.

  1. The sensitivity of the fecal occult blood test (FOBT) is reported to be 0.68. What is the False Negative Rate?
  2. The specificity of the fecal occult blood test (FOBT) is reported to be 0.98. What is the False Positive Rate?
  3. For men between 50 and 54 years of age, the rate of colon cancer is 61 per 100,000. If the false negative rate of the fecal occult blood test (FOBT) is 10%, how many persons who have colon cancer will test negative?
  4. For men between 50 and 54 years of age, the rate of colon cancer is 61 per 100,000. If the false positive rate of the fecal occult blood test (FOBT) is 10%, how many persons who do not have colon cancer will test positive?
  5. A study was conducted to see if mammograms reduced mortality
    Mammogram Deaths/1000 women
    No 4
    Yes 3

    data from Table 5-1 p. 60 Gigerenzer (2002)
    What is the RRR?

  6. A study was conducted to see if mammograms reduced mortality
    Mammogram Deaths/1000 women
    No 4
    Yes 3

    data from Table 5-1 p. 60 Gigerenzer (2002)
    What is the NNT?

  7. Does supplemental Vitamin C decrease risk of stroke in Type II diabetic women? A study conducted on 1923 women, a total of 57 women had a stroke, 14 in the normal Vitamin C level and 32 in the high Vitamin C level. What is the NNT between normal and high supplemental Vitamin C groups?
  8. Sensitivity of a test is defined as
    A. False Positive Rate
    B. True Positive Rate
    C. False Negative Rate
    D. True Negative Rate
  9. Specificity of a test is defined as
    A. False Positive Rate
    B. True Positive Rate
    C. False Negative Rate
    D. True Negative Rate
  10. In thinking about the results of a test of a null hypothesis, Type I error rate is equivalent to
    A. False Positive Rate
    B. True Positive Rate
    C. False Negative Rate
    D. True Negative Rate
  11. During the Covid-19 pandemic, number of reported cases each day were published. For example, 155 cases were reported for 9 October 2020 by Department of Health. What is the raw incident rate?

Quiz Chapter 7.3

Conditional Probability and Evidence Based Medicine


Chapter 7 contents

7.1 – Epidemiology definitions

Introduction

This subchapter may lack for drama, but let’s start by providing a list of key terms with definitions as you start our introduction to epidemiology. More definitions will follow in the sections as well.

Definitions

Absolute risk: The probability that a specified event will occur in a specified population. See Ch07.4 – Epidemiology: Relative risk and absolute risk, explained.

Absolute risk reduction (ARR): the decrease in risk of an event in an exposed (treatment) group compared to an unexposed (control) group. Also called the risk difference. CER-EER, see Contingency table. See Ch07.4 – Epidemiology: Relative risk and absolute risk, explained.

CER \ \& \ EER: Control Event Rate and Experimental Event Rate. In observational studies, transition from “control” and “experimental” to exposure terms. For example, prospective or retrospective cohort studies, EER is Exposed Event Rate and its partner UER, Unexposed Event Rate. Equivalently, you will encounter I_{e} for Incidence in the Exposed and I_{u} forIncidence in the Unexposed. For Case-Control studies, where the direct event (incidence) rates over time are unavailable, then EER becomes Exposure Rate in Cases — the proportion of people with the condition who were exposed to the risk factor and CER is now Exposure Rate in Controls.

Contingency table, also called cross tabulation or crosstab, is a display of counts of variables in a matrix format. We briefly introduced the contingency table in Chapter 5.1. In epidemiology, rows of contingency table represent treatment or exposure groups, columns represent outcomes.

Table 1. A 2 X 2 contingency table

Outcome
Yes No
Treatment or exposed group a b
Control or nonexposed group c d

The 2X2 contingency table is referred to frequently in this chapter and again in Chapter 9.

R code

a = 4; b = 46; c = 5; d = 45

Table1 <- matrix(c(a,b,c,d), 2, 2, byrow=TRUE, dimnames = list(c("Treatment", "Control"), c("Yes", "No"))); Table1

R output

          Yes  No
Treatment   4  46
Control     5  45

In statistical classification, a field dedicated to establishing algorithms for correctly identifying and predicting classes of data, eg, correct disease diagnosis or , the 2X2 contingency table is often called a confusion or error matrix (Greene 2003). Machine learning methods are often built on developments from statistical classification findings (Michie et al 1995). We expand on contingency tables in Chapter 7.4 and Chapter 9.2.

Note 1: First discussed in Chapter 5.1, by convention, the standard format for an epidemiological 2×2 contingency table organizes exposure on the rows and disease outcome on the columns as follows:

  • Rows (Exposure): The top row represents Exposed / Treatment (Yes), and the bottom row represents Non-exposed / Control (No).
  • Columns (Outcome): The left column represents Disease / Case (Yes), and the right column represents No Disease / Control (No). See Chapter 7.

Control event rate (CER): How often an event occurs in the control group.  \frac{c}{c+d}, see Contingency table.

Diagnosis: identification of the nature of a disease or condition.

Event: From probability theory, an event is a set of one or more outcomes to which a probability is assigned to each outcome.

Experimental event rate (EER): How often an event occurs in the treatment group. \frac{a}{a+b}, see Contingency table.

Exposure risk: the potential for harm from contact with or vulnerability to a hazard or risk factor.

Hazard: anything that can cause harm.

Incidence: the number of newly diagnosed individuals in a population having a condition, disease or other characteristic. Compare to prevalence.

Likelihood: In every-day English, the term likelihood and probability mean the same thing — the chance that an event will occur. In statistics, however, probability refers to possible outcomes in the future — a prediction for an event to occur, whereas likelihood is associated with the possible explanation (hypothesis) for the outcome that has already occurred, the past. Put another way, likelihood quantifies how likely is the data we observe, given the hypothesis (cf. excellent discussion by Gallistel 2015)? We will look at likelihood methods in practice in subsequent chapters.

Negative predictive value of a test (NPV), defined as the probability that a negative test result identifies a person who truly does not have the disease. Calculated as the total number of individuals without the disease divided by the total that tested negative.  NPV = \frac{TN}{TN+FN}

Number needed to treat (NNT): the inverse of the absolute risk reduction. NNT = \frac{1}{ARR}. See Ch07.4 – Epidemiology: Relative risk and absolute risk, explained.

Odds, the ratio (OR) of two probabilities: the probability of getting a one on throwing a dice is 1\6, the probability of not getting a one is 5\6, therefore the odds of getting a one are 1 to 5.  OR = \frac{a \cdot d}{b \cdot c}. See Ch07.5 – Odds ratio.

Outcome, the single result from a random experiment. For example, result of a single coin toss is “heads.” Results of a birth, the outcome is the child born is a singleton, single birth.

Per capita rate, Latin phrase, for each head, meaning per person.

Positive predictive value of a test (PPV), defined as the probability that a positive test result identifies a person who truly has the disease. Calculated as the total number of individuals with the disease divided by the total that tested positive. PPV = \frac{TP}{TP+FP}

Posttest probability refers to the probability that the patient has the disease after the results of the test are known.

Pretest probability is the prevalence of the disease, ie, the chance that the a randomly selected person from the population has the disease.

Prevalence: The proportion of individuals in a population having a condition, disease, or characteristic. Compare to incidence.

Probability, defined in Chapter 6.1.

Prognosis, how a disease plays out.

Relative risk: Ratio of the risk of an event among those exposed to the risk factor to the risk among those not exposed to the risk factor. See Ch07.4 – Epidemiology: Relative risk and absolute risk, explained.

Relative risk reduction (RRR): is a measure calculated by dividing the absolute risk reduction by the control event rate. See Ch07.4 – Epidemiology: Relative risk and absolute risk, explained.

Risk: Probability of an event. Risk is not restricted to just bad events, but refers to the uncertainty of a particular event (eg, the risk that a child will be born male seems a melodramatic statement, but it is accurate as far as this definition goes).

Therapy, treatment intended to treat, relieve, or cure a disorder of condition.

Questions

  1. Compare and contrast ARR and RRR.
  2. What’s the difference between event, hazard, and risk?
  3. What’s the difference between incidence and prevalence?
  4. What’s the difference between diagnosis and prognosis?
  5. What’s the implication of a NNT greater than 100 in terms of the utility of a proposed therapy or treatment?

Quiz

Quiz Chapter 7.1

Epidemiology definitions


Chapter 7 contents